Published in final edited form as:

Org Lett. 2011 September 2; 13(17): 4538–4541. doi:10.1021/ol2017005.

Assignment and Stereocontrol of Hibarimicin Atropoisomers

Ian M. Romaine[§], Jonathan E. Hempel[§], Ganesh Shanmugam[§], Hiroshi Hori[≠], Yasuhiro Igarashi[#], Prasad L. Polavarapu[§], and Gary A. Sulikowski^{*,§}

Departments of Chemistry and Biochemistry, Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN 37235, USA, Biotechnology Research Center, Toyoma Prefectural University, Kosugi, Toyama 939-0398, Japan and Graduate School of Agriculture, Tamagawa University, Machida, Tokyo 194-8610, Japan

Abstract

A stereochemical feature of the hibarimicins is a central biaryl (HMP-Y6) or aryl-quinone (hibarimicinone) incorporated as a single atropodiastereomer. Herein, a chiral resolution and deracemization process to access optically enriched biaryls *aR*-3 and *aS*-3 is described. From these atropoenantiomers the BCD-EFG ring system of HMP-Y6 is constructed [(+)-*aR*-7]. Comparison of CD spectra of *aR*-7 to HMP-Y6 leads to the assignment of HMP-Y6 and hibarimicin B atropoisomers as *aR* and *aS*, respectively.

The hibarimicins were isolated from the soil microbe *Microbispora rosea* during the course of screening natural product extracts for tyrosine kinase inhibitors.^{1,2} Structural studies on hibarimicins A, B, C, D and G concluded that the five metabolites shared a common aglycone [hibarimicinone (Figure 1)] conjugated to six deoxy sugars located at C10/C12 and C10'/C12'.^{1b} The relative stereochemistry of the aglycone hibarimicinone was assigned as shown in Figure 1 with the configuration of the C13 tertiary alcohol (H ring) tentative. Kajiura and co-workers later reported on biosynthetic studies using blocked mutants of the hibarimicin producer *Microbispora rosea* subsp. *hibaria* TP-A0121 that proved the C13 (H ring) and C13' (A ring) stereochemistry were identical.³ Key to clarification of C13 stereochemistry was the isolation of HMP-Y6 (Figure 1),^{3c} a glycosylated C₂-symmetric shunt metabolite, derived from the oxidative homocoupling of an aromatic undecaketide followed by glycosylation. Acidic methanolysis of HMP-Y6 resulted in release of C10/C12 and C10'/C12' deoxy sugars to provide the aglycone (HMP-Y1, Figure 1). Comparison of the core biaryl substitution pattern of HMP-Y6 to known atropisomeric natural products such as biphysson⁴ support an atropodiastereoselective oxidative homocoupling followed by oxidation of the BCD ring system leading to hibarimicinone with retention of atropo configuration.⁵ In connection with our pursuit of a total synthesis of hibarimicinone⁶ we describe here a deracemization method providing atropo-stereocontrol and assignment of

gary.a.sulikowski@vanderbilt.edu.

[§]Vanderbilt University

[#]Toyoma Prefectural University

[≠]Tamagawa University

configuration of the central biaryl carbon-carbon bond of HMP-Y6 and hibarimicin B by spectroscopic correlation further supported by computational studies.

A variety of naturally occurring dimeric quinones, biaryls and binaphthoquinones have been identified and the subject of synthetic investigations.⁷ In general two approaches have been utilized in their assembly: oxidative biomimetic homocouplings⁸ and two-directional annulations⁹ (Figure 2). Non-enzymatic biomimetic homocouplings of 2-naphthols have provided diastereoselectivity under substrate control but diastereoselective homocouplings of 1-naphthols, as required for HMP-Y1 (Figure 2), have not been reported.¹⁰ Müller and Steglich^{9a,b} have employed two-directional Michael-Dieckmann cyclizations of optically active biaryl *o*-toluate esters obtained by resolution. For the purpose of assigning absolute stereochemistry of the central biaryl bond of HMP-Y1 our studies began with a two-directional annulation strategy starting from single atropoenantiomers of bis-*o*-tolyl phenyl benzoate.

Despite the importance of biaryl atropisomers as chiral ligands and their frequent occurrence in nature control of axial chirality remains challenging and no general methods are currently available to directly produce the required bis-*o*-tolyl phenyl benzoate enantioselectively (Figure 2).¹¹ For this reason we considered chiral resolution as it would provide access to both enantiomers and assist in assigning the absolute stereochemistry of HMP-Y1. To begin we examined the Spring oxidative organocuprate homocoupling starting from a series of protected phenols (**1a–c**) (Scheme 1).¹² Lithiation, cupration and oxidation of methyl ether **1a** provided biaryl **2a** in yields ranging from 51 to 63%, while cuprates derived from MOM (**1b**) and benzyl (**1c**) ethers oxidatively coupled in slightly lower yields. Phenyl ester **3** was derived from biaryl **2a** by bromination followed by a lithium-halogen exchange and phenyl chloroformate quench. We examined the resolution of biaryl intermediates en route to **3** and bis-phenyl ester **3** by chiral LC using several chiral solid-supports. Resolution of enantiomers was observed only with bis-phenyl ester **3**, which could be separated on preparative scale. In order to assign the absolute stereochemistry of (+)- and (–)-phenyl benzoate **3**, bis-phenol (±)-**4** [from either MOM ether **2b** (HCl, MeOH) or benzyl ether **2c** (H₂, Pd/C)] was condensed with an excess of (*S*)-Mosher acid to give diastereomers *aR*-**5** and *aS*-**6**. The latter diastereomer was recrystallized from ether-dichloromethane and subject to single-crystal x-ray analysis allowing unambiguous assignment of stereochemistry. Phenol *aS*-**4** was derived from Mosher ester *aS*-**6** by LAH reduction and advanced to *aS*-**3** by a three-step reaction sequence (Scheme 3). Atropoenantiomer *aS*-**3** correlated with the slower eluting enantiomer in the chiral-LC resolution of biaryl (±)-**3** described above.

Having assigned the absolute configuration of (–)-*aS*-**3** and (+)-*aR*-**3**, we turned our attention to developing a method of accessing enantiomerically enriched **3** not relying on a chiral resolution. We were drawn to reports describing copper(II)-diamine complexes to deracemize C₂-symmetric ligands including BINOL, VAPOL and VANOL.¹³ Typically deracemization is accomplished by in situ generation of copper(II)-(–)-sparteine by the aerobic sonication of CuCl and (–)-sparteine followed by exposure of this complex to the racemic biaryl. While this method has been applied to chiral ligands^{13a,b} and oligonaphthalenes¹⁴ no report of reagent-controlled deracemization in the context of a natural product synthesis has appeared.¹⁵ We were pleased to observe exposure of racemic biphenol **4** to copper(II)-(–)-sparteine complex resulted in isolation of (–)-*aS*-**4** in 93% ee¹⁶ and 77% yield. When (±)-**4** was treated with copper(II) complexed to O'Briens diamine¹⁷ [(+)-sparteine surrogate] (+)-*aR*-**4** was produced in 80% ee (85% yield).

In order to evaluate the proposed bis-annulation (Figure 2) we optimized conditions for the generation of the bis-*o*-toluate anion¹⁸ derived from **3** using a series of deprotonation conditions followed by a D₂O quench.¹⁹ Interestingly, no deprotonation was observed using

one or two equivalents of LDA-TMEDA complex, however use of four equivalents of LDA-TMEDA resulted in generation of the bis-toluate anion as demonstrated by near complete deuterium incorporation. Addition of two equivalents of cyclohexenone to the bis-toluate anion derived from (+)-*aR*-**3** followed by DDQ oxidation provided (+)-*aR*-**7**. Subsequently racemic ($\pm$)-**7** was resolved using chiral-LC on a preparative scale to give optically pure (–)-*aS*-**7** and (+)-*aR*-**7**.

Biaryl dimers (–)-*aS*-**7** and (+)-*aR*-**7** constitute the BCD-EFG sub-structure of HMP-Y6 (Figure 1). Furthermore, since **7** incorporates the chromophore of HMP-Y6 we anticipated that the quantum chemical predictions of ECD spectra for single enantiomers of **7** and comparison of the CD-spectrum of HMP-Y6 to *aS*-**7** and *aR*-**7** would allow assignment of configuration of the HMP-Y6 atropisomer. The experimental electronic circular dichroism (ECD) spectra of *aS*-**7** and *aR*-**7**, along with quantum chemical prediction for *aR*-**7**, are shown in Figure 3. A bisignate negative ECD couplet (negative ECD band on the long wavelength side and positive ECD band on the short wavelength side) was observed, as also predicted, for *aR*-**7**. The negative ECD couplet predicted by the quantum chemical calculations for negative torsional angle between the planes of two biaryl moieties in *aR*-**7** is in agreement with the same relation predicted for the transition dipole moments by the empirical exciton coupling model.²⁰ Finally, the CD spectrum of HMP-Y6²¹ correlates with *aR*-**7** with both having negative torsional angle between the planes of two biaryl moieties.

In summary, the axial chirality of HMP-Y6 has been assigned the *aR* configuration and assuming the configuration is retained upon oxidation to hibarimicin, the latter can be assigned the *aS* configuration.²² To date, all isolated hibarimicins share the same UV and CD spectrum indicating they also possess the *aS* configuration. Heating a methanol solution of hibarimicinone in methanol (60 °C) resulted in isomerization to the unnatural *aR* isomer, indicating the hibarimicinone atropodiastereomer *aS* is not a thermodynamic product. This observation will need to be taken into account when designing a total synthesis of hibarimicinone or HMP-Y1.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the National Institutes of Health (CA 059515), National Science Foundation (CHE-0804301) and the Vanderbilt Institute of Chemical Biology. This work was conducted in part using the resources of the Advanced Computing Center for Research and Education at Vanderbilt University, Nashville, TN.

References

1. (a) Kajiura T, Furumai T, Igarashi Y, Hori H, Higashi K, Ishiyama T, Uramoto M, Uehara Y, Oki T. J Antibiot. 1998; 51:394–401. [PubMed: 9630861] (b) Hori H, Igarashi Y, Kajiura T, Furumai T, Higashi K, Ishiyama T, Uramoto M, Uehara Y, Oki T. J Antibiot. 1998; 51:402–417. [PubMed: 9630862]
2. Hibarimicin B is identical to previously reported angelmicin B, see: (a) Uehara Y, Li P, Fukazawa H, Mizuno S, Nihei Y, Nishio M, Hanada M, Yamamoto C, Furumai T, Oki T. J Antibiot. 1993; 46:1306–1308. [PubMed: 8407594] (b) Hori H, Higashi K, Ishiyama T, Uramoto M, Uehara Y, Oki T. Tetrahedron Lett. 1996; 37:2785–2788.
3. (a) Hori H, Kajiura T, Igarashi Y, Furumai T, Higashi K, Ishiyama T, Uramoto M, Uehara Y, Oki T. J Antibiot. 2002; 55:46–52. [PubMed: 11918065] (b) Kajiura T, Furumai T, Igarashi Y, Hori H, Higashi K, Ishiyama T, Uramoto M, Uehara Y, Oki T. J Antibiot. 2002; 55:53–60. [PubMed: 11918066] (c) Igarashi Y, Kajiura T, Furumai T, Hori H, Higashi K, Ishiyama T, Uramoto M, Uehara Y, Oki T. J Antibiot. 2002; 55:61–70. [PubMed: 11918068]

4. Hauser F, Gauuan P. *Org Lett.* 1999; 1:671–672. [PubMed: 10823198]
5. For earlier discussions on hibarimicin atropoisomers, see: (a) Maharoof U, Sulikowski G. *Tetrahedron Lett.* 2003; 44:9021–9023. (b) Narayan S, Roush W. *Org Lett.* 2004; 6:3789–3792. [PubMed: 15469350]
6. Synthetic studies on the hibarimicins. (a) Lee C, Audelo M, Reibenpies J, Sulikowski G. *Tetrahedron.* 2002; 58:4403–4409. (b) Kim K, Maharoof U, Raushel J, Sulikowski G. *Org Lett.* 2003; 5:2777–2780. [PubMed: 12889872] (c) Lambert W, Roush W. *Org Lett.* 2005; 7:5501–5504. [PubMed: 16288541] (d) Lee W, Kim K, Sulikowski G. *Org Lett.* 2005; 7:1687–1689. [PubMed: 15844881] (e) Li J, Todaro LJ, Mootoo DR. *Org Lett.* 2008; 10:1337–1340. [PubMed: 18324819]
7. (a) Bringmann G, Mortimer A, Keller P, Gresser M, Garner J, Breuning M. *Angew Chem, Int Ed.* 2005; 44:5384–5427. (b) Bringmann G, Tasler S. *Tetrahedron.* 2001; 57:331–343. (c) Bringmann G, Gulder T, Gulder TAM, Breuning M. *Chem Rev.* 2011; 111:563–639. [PubMed: 20939606]
8. (a) Drochner D, Hüttel W, Nieger M, Müller M. *Angew Chem, Int Ed.* 2003; 42:931–933. (b) Sperry J, Sejberg JJP, Stiemke FM, Brimble MA. *Org Biomol Chem.* 2009; 7:2599–2603. [PubMed: 19503935]
9. (a) Bode SE, Drochner D, Müller M. *Angew Chem, Int Ed.* 2007; 46:5916–5920. (b) Drochner D, Hüttel W, Bode SE, Mueller M, Karl U, Nieger M, Steglich W. *Eur J Org Chem.* 2007:1749–1758. (c) Govender S, Mmutlane EM, van Otterlo WAL, de Koning CB. *Org Biomol Chem.* 2007; 5:2433–2440. [PubMed: 17637963]
10. For examples of stereoselective 2-naphthol homocouplings, see: (a) Kozlowski MC, Morgan BJ, Linton EC. *Chem Soc Rev.* 2009; 38:3193–3207. [PubMed: 19847351] (b) Young S, Grove C, Gozalez M, Urgaonkar S, Fetting J, Shaw J. *Angew Chem, Int Ed.* 2011; 50:3730–3733.
11. Wallace TW. *Org Biomol Chem.* 2006; 4:3197–3210. [PubMed: 17036104]
12. (a) Surry D, Fox D, Macdonald S, Spring D. *J Chem Soc, Chem Commun.* 2005:2589–2590. (b) Surry D, Spring D. *Chem Soc Rev.* 2006; 35:218–225. [PubMed: 16505916]
13. (a) Zhang Y, Yeung SM, Wu H, Heller DP, Wu C, Wulff WD. *Org Lett.* 2003; 5:1813–1816. [PubMed: 12762659] (b) Hu G, Holmes D, Gendhar BF, Wulff WD. *J Am Chem Soc.* 2009; 131:14355–14364. [PubMed: 19754056] (c) Lee WK, Park YS, Beak P. *Acc Chem Res.* 2009; 42:224–234. [PubMed: 19152329]
14. (a) Smrcina M, Lorenc M, Hanus V, Sedmera P, Kocovsky P. *J Org Chem.* 1992; 57:1917–1920. (b) Smrcina M, Polakova J, Vyskocil S, Kocovsky P. *J Org Chem.* 1993; 58:4534–4538.
15. Nelson and Meyers were the first to report on the copper(II)-mediated deracemization of biaryls under substrate control, see: Nelson TD, Meyers AI. *Tetrahedron Lett.* 1994; 35:3259–3262.
16. Enantiomeric excess was determined by analysis of the derived bis-menthyl carbonate. See supporting information for details.
17. Dearden M, Firkin C, Hermet J, O'Brien P. *J Am Chem Soc.* 2002; 124:11870–11871. [PubMed: 12358529]
18. (a) Charest M, Lerner C, Brubaker J, Siegel D, Myers A. *Science.* 2005; 308:395–398. [PubMed: 15831754] (b) Mal D, Pahari P. *Chem Rev.* 2007; 107:1892–1918. [PubMed: 17444689]
19. Romaine, IM. PhD Dissertation. Vanderbilt University; 2011.
20. Harada, N.; Nakanishi, K. *Circular dichroic spectroscopy: Exciton coupling in organic stereochemistry.* University Science Books; Mill Valley, CA: 1983.
21. See supporting information.
22. Note, the difference in configurational assignment between HMP-Y1 (*aR*) and hibarimicinone (*aS*) results from a switch in group priorities in accord with the Cahn-Ingold-Prelog sequence rules.

Figure 1.
Structures of hibarimicinone, hibarimicins A-D, HMP-Y6 and HMP-Y1.

Figure 2.
Biomimetic and two-directional strategies directed toward HMP-Y1.

Figure 3.

ECD and absorption spectra of **7**. Top panel: quantum chemical prediction of ECD spectrum for *aR*-**7** at B3LYP/6-31G* level; Middle two panels: experimental ECD and absorption spectra of *aS*-**7** (blue) and *aR*-**7** (red); Bottom panel: quantum chemical prediction of absorption spectrum for *aR*-**7**. The inset in the top panel shows the structure of lowest energy conformation of *aR*-**7** at B3LYP/6-31G* level.

Scheme 1.
Preparation and resolution of biaryl **3**.

Scheme 2. Absolute configuration assignment and deracemization route to $(+)\text{-aS-3}$.

Scheme 3.
Bis-annulation leading to BCDEFG ring system.